In this study, new mesenchymal stem cell lines were developed to allow for infection by genetically modified adenoviruses and replication. These new stem lines were completed by loading them with GMCSF, Flt3L-TRAIL, shTGFβ, and shHSP, joint expression gene transporters that the researchers conducting this study had previously developed. Thus, this study was conducted on mesenchymal stem cell lines loaded with GMCSF, Flt3L-TRAIL, shTGFβ, and shHSP and designed to allow for adenovirus infection and drastically increased replication.
When using the mesenchymal stem cell lines developed using this technology, the rate of infection was significantly increased, thus indicating the suitability of these cells for use in anti-cancer treatments. Furthermore, the introduction of the GM-CSF, Flt3L-TRAIL, shTGF-β, and shHSP joint expression gene transporters (YSC-02) that the researchers who conducted this study had previously discovered to the modified stem cell lines enabled their use as new anti-cancer treatment options and had the secondary effect of improved replication rates. Such anti-cancer treatments have been garnering great interest in cancer immunotherapy research. With further preclinical research, such treatments and their supporting domestic infrastructure and related techniques can be further developed for production. Most importantly, these virus-based anticancer medications can be used to treat metastatic tumors, which are the main cause of death among cancer patients.